Smoking Cessation Pipeline Analysis 2018 - Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Recent Developments

Published:  Mar 2020 Report Code: KSI061611381 Pages: 114

Smoking Cessation Pipeline Analysis report covers 12 drugs currently in different phases of development. Smoking cessation means discontinuing or quitting smoking which is generally difficult and prolonged due to nicotine addiction. Smoking is the most common preventable cause of death. Quitting requires in general several attempts. People who discontinue often start again because of withdrawal symptoms such as nicotine cravings, weight gain, stress, anxiety etc. Strategies to hep quit smoking includes behavioural counselling, and medications such as nicotine replacement therapy and also quitting without assistance.  

The report provides smoking cessation drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market. Major industry players profiled as part of the report are Selecta Biosciences, Inc, Lotus Pharma, Bioprojet SCR among others.

Scope:

By Company


By Phase

NDA filed

Phase III

Phase II

Phase I

Pre-clinical

Discovery


By Molecule Type

Small molecules

Biologics

Peptides or Small proteins


By Region

North America

South America

Europe

Middle East and Africa

Asia Pacific


By Route of Administration

IV

IM

S/C

Oral

Intratumoral

* There may be changes in final report as per availability of the data

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development 
5.2.1.1. Introduction
5.2.1.1.1. Drug Profile
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Aradigm Corporation
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. 22nd Century Limited, LLC
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Chrono Therapeutics, Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Invion, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Selecta Biosciences, Inc
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Achieve Life Sciences, Inc
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Embera NeuroTherapeutics, Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Lavipharm
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Lotus Pharma
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Ethismos Research Inc.
6.10.1. Introduction
6.10.2. Financials

Aradigm Corporation
22nd Century Limited, LLC
Chrono Therapeutics, Inc.
Invion, Inc.
Selecta Biosciences, Inc
Achieve Life Sciences, Inc
Embera NeuroTherapeutics, Inc.
Lavipharm
Lotus Pharma
Ethismos Research Inc.

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us